These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27297738)

  • 1. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y; Ogawa O; Oyama Y
    Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
    Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
    Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
    Sakai G; Saito D; Nakajima R; Hatano M; Noguchi Y; Kurihara S; Katayama S; Inoue I; Noda M; Shimada A
    J Diabetes Investig; 2018 Mar; 9(2):448-449. PubMed ID: 29504279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
    Munakata W; Ohashi K; Yamauchi N; Tobinai K
    Int J Hematol; 2017 Mar; 105(3):383-386. PubMed ID: 27696192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
    Shiba M; Inaba H; Ariyasu H; Kawai S; Inagaki Y; Matsuno S; Iwakura H; Yamamoto Y; Nishi M; Akamizu T
    Intern Med; 2018 Jul; 57(14):2029-2034. PubMed ID: 29491310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New-onset insulin-dependent diabetes due to nivolumab.
    Zaied AA; Akturk HK; Joseph RW; Lee AS
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29623210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S; Kuriyama A; Tachibana H
    J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
    Sakaguchi C; Ashida K; Yano S; Ohe K; Wada N; Hasuzawa N; Matsuda Y; Sakamoto S; Sakamoto R; Uchi H; Furue M; Nomura M; Ogawa Y
    Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
    Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
    J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
    Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
    Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
    Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
    J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
    Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.